{
  "company": {
    "name": "Dermavant",
    "website": "https://dermavant.com/",
    "record": "https://startuphistory.org/c/dermavant.com"
  },
  "status": null,
  "history_since": "2011-02-02T10:41:54.000Z",
  "baseline": {
    "snapshot_id": "eacc49e9fe2cbb533d83ef98677ea65a883364be371c7919f8988bb59e1f3200",
    "observed_at": "2011-02-02T10:41:54.000Z",
    "headline": "dermavant.com",
    "description": null,
    "evidence": "https://web.archive.org/web/20110202104154/http://dermavant.com/",
    "evidence_kind": "internet_archive",
    "facts": {
      "version": 1,
      "pages": [
        {
          "page": "home",
          "customers": [],
          "investors": [],
          "prices": [
            "$4.99 / mo",
            "$1.19 / mo"
          ],
          "compliance": [],
          "funding": []
        }
      ]
    },
    "basis": "first_observation",
    "is_change": false
  },
  "live_captures": 1,
  "last_checked": "2026-11-05T13:25:50.690Z",
  "live_status": null,
  "messaging": [
    {
      "quote_observed_at": "2019-01-19T12:17:37.000Z",
      "variants": [
        {
          "headline": "dermavant.com",
          "subhead": null,
          "observed_at": "2011-02-02T10:41:54.000Z",
          "evidence": "https://web.archive.org/web/20110202104154/http://dermavant.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "DERMAVANT SCIENCES",
          "subhead": "Dermavant Sciences is a leader in the development of new potential treatments in medical dermatology focusing on Atopic Dermatitis and potential treatments.",
          "observed_at": "2017-09-18T17:56:00.000Z",
          "evidence": "https://web.archive.org/web/20170918175600/https://dermavant.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Dermavant Sciences Announces Appointment of Dr. Philip M. Brown as Chief Medical Officer",
          "subhead": "Home",
          "observed_at": "2019-01-19T12:17:37.000Z",
          "evidence": "https://web.archive.org/web/20190119121737/https://dermavant.com/",
          "evidence_kind": "internet_archive"
        }
      ],
      "headline": "Dermavant Sciences Announces Appointment of Dr. Philip M. Brown as Chief Medical Officer",
      "subhead": "Home",
      "from": "2011-02-02T10:41:54.000Z",
      "to": "2019-01-19T12:17:37.000Z",
      "captures": 3,
      "evidence": "https://web.archive.org/web/20190119121737/https://dermavant.com/",
      "evidence_kind": "internet_archive",
      "seen": {
        "between": {
          "from": "2011-02-02T10:41:54.000Z",
          "to": "2019-01-19T12:17:37.000Z"
        }
      },
      "current": false
    },
    {
      "quote_observed_at": "2020-04-09T15:17:34.000Z",
      "variants": [
        {
          "headline": "Robust Pipeline",
          "subhead": null,
          "observed_at": "2020-04-09T15:17:34.000Z",
          "evidence": "https://web.archive.org/web/20200409151734/https://www.dermavant.com/",
          "evidence_kind": "internet_archive"
        }
      ],
      "headline": "Robust Pipeline",
      "subhead": null,
      "from": "2020-04-09T15:17:34.000Z",
      "to": "2020-04-09T15:17:34.000Z",
      "captures": 1,
      "evidence": "https://web.archive.org/web/20200409151734/https://www.dermavant.com/",
      "evidence_kind": "internet_archive",
      "seen": {
        "on": "2020-04-09T15:17:34.000Z"
      },
      "current": false
    },
    {
      "quote_observed_at": "2021-01-19T11:36:58.000Z",
      "variants": [
        {
          "headline": "Patient‑Focused Innovation",
          "subhead": null,
          "observed_at": "2021-01-19T11:36:58.000Z",
          "evidence": "https://web.archive.org/web/20210119113658/https://www.dermavant.com/",
          "evidence_kind": "internet_archive"
        }
      ],
      "headline": "Patient‑Focused Innovation",
      "subhead": null,
      "from": "2021-01-19T11:36:58.000Z",
      "to": "2021-01-19T11:36:58.000Z",
      "captures": 1,
      "evidence": "https://web.archive.org/web/20210119113658/https://www.dermavant.com/",
      "evidence_kind": "internet_archive",
      "seen": {
        "on": "2021-01-19T11:36:58.000Z"
      },
      "current": false
    },
    {
      "quote_observed_at": "2022-01-03T15:50:39.000Z",
      "variants": [
        {
          "headline": "Dermavant Announces Publication of PSOARING 1 & 2 Pivotal Studies of Tapinarof in Plaque Psoriasis in The New England Journal of Medicine",
          "subhead": "Dermavant Sciences is a clinical-stage biopharmaceutical company committed to developing innovative therapeutics in immuno-dermatology.",
          "observed_at": "2022-01-03T15:50:39.000Z",
          "evidence": "https://web.archive.org/web/20220103155039/https://www.dermavant.com/",
          "evidence_kind": "internet_archive"
        }
      ],
      "headline": "Dermavant Announces Publication of PSOARING 1 & 2 Pivotal Studies of Tapinarof in Plaque Psoriasis in The New England Journal of Medicine",
      "subhead": "Dermavant Sciences is a clinical-stage biopharmaceutical company committed to developing innovative therapeutics in immuno-dermatology.",
      "from": "2022-01-03T15:50:39.000Z",
      "to": "2022-01-03T15:50:39.000Z",
      "captures": 1,
      "evidence": "https://web.archive.org/web/20220103155039/https://www.dermavant.com/",
      "evidence_kind": "internet_archive",
      "seen": {
        "on": "2022-01-03T15:50:39.000Z"
      },
      "current": false
    },
    {
      "quote_observed_at": "2023-09-26T18:06:58.000Z",
      "variants": [
        {
          "headline": "Dermavant Reports Positive Topline Results from ADORING 1, the Second Atopic Dermatitis Phase 3 Trial of VTAMA ® (tapinarof) Cream, 1% in Adults and Children as Young as 2 Years Old",
          "subhead": "Dermavant Sciences is a clinical-stage biopharmaceutical company committed to developing innovative therapeutics in immuno-dermatology.",
          "observed_at": "2023-09-26T18:06:58.000Z",
          "evidence": "https://web.archive.org/web/20230926180658/https://www.dermavant.com/",
          "evidence_kind": "internet_archive"
        }
      ],
      "headline": "Dermavant Reports Positive Topline Results from ADORING 1, the Second Atopic Dermatitis Phase 3 Trial of VTAMA ® (tapinarof) Cream, 1% in Adults and Children as Young as 2 Years Old",
      "subhead": "Dermavant Sciences is a clinical-stage biopharmaceutical company committed to developing innovative therapeutics in immuno-dermatology.",
      "from": "2023-09-26T18:06:58.000Z",
      "to": "2023-09-26T18:06:58.000Z",
      "captures": 1,
      "evidence": "https://web.archive.org/web/20230926180658/https://www.dermavant.com/",
      "evidence_kind": "internet_archive",
      "seen": {
        "on": "2023-09-26T18:06:58.000Z"
      },
      "current": false
    },
    {
      "quote_observed_at": "2024-07-01T17:46:01.000Z",
      "variants": [
        {
          "headline": "Dermavant Announces Approval of Tapinarof in both Psoriasis and Atopic Dermatitis in Japan",
          "subhead": "Dermavant uses science with breakthrough innovations and challenging the standard of care in immuno-dermatology to treat chronic skin conditions.",
          "observed_at": "2024-07-01T17:46:01.000Z",
          "evidence": "https://web.archive.org/web/20240701174601/https://dermavant.com/",
          "evidence_kind": "internet_archive"
        }
      ],
      "headline": "Dermavant Announces Approval of Tapinarof in both Psoriasis and Atopic Dermatitis in Japan",
      "subhead": "Dermavant uses science with breakthrough innovations and challenging the standard of care in immuno-dermatology to treat chronic skin conditions.",
      "from": "2024-07-01T17:46:01.000Z",
      "to": "2024-07-01T17:46:01.000Z",
      "captures": 1,
      "evidence": "https://web.archive.org/web/20240701174601/https://dermavant.com/",
      "evidence_kind": "internet_archive",
      "seen": {
        "on": "2024-07-01T17:46:01.000Z"
      },
      "current": false
    },
    {
      "quote_observed_at": "2026-11-05T13:25:50.690Z",
      "variants": [
        {
          "headline": "Organon, here for her health",
          "subhead": "Organon is a global health care company dedicated to making a world of difference for women, their families and the communities they care for.",
          "observed_at": "2026-11-05T13:25:50.690Z",
          "evidence": "https://www.organon.com/",
          "evidence_kind": "live_capture"
        }
      ],
      "headline": "Organon, here for her health",
      "subhead": "Organon is a global health care company dedicated to making a world of difference for women, their families and the communities they care for.",
      "from": "2026-11-05T13:25:50.690Z",
      "to": "2026-11-05T13:25:50.690Z",
      "captures": 1,
      "evidence": "https://www.organon.com/",
      "evidence_kind": "live_capture",
      "seen": {
        "on": "2026-11-05T13:25:50.690Z"
      },
      "current": true
    }
  ],
  "changes": [
    {
      "n": 1,
      "id": "page-eacc49e9fe2cbb533d83ef98677ea65a883364be371c7919f8988bb59e1f3200:8120f17026d9ebb4cada86d953765b5c89c5ab52ce24b45fff148d5a1a0fb11f:hiring:20dd4c09cc4ab0aa",
      "before_evidence": "https://web.archive.org/web/20110202104154/http://dermavant.com/",
      "before_evidence_kind": "internet_archive",
      "kind": "hiring",
      "label": "Hiring",
      "summary": "Added a careers page.",
      "between": {
        "from": "2011-02-02T10:41:54.000Z",
        "to": "2017-09-18T17:56:00.000Z"
      },
      "evidence": "https://web.archive.org/web/20170918175600/https://dermavant.com/",
      "evidence_kind": "internet_archive",
      "basis": "page_facts",
      "topic": "https://startuphistory.org/t/added-careers-page"
    },
    {
      "n": 2,
      "id": "page-c465701266f3f2572058d47ec7473e1e9945e124e41528add2a803d73a8b76c1:ffef952de19cba2647f936fb4350b654383ef374d9d8b7315b7885cf7ca13e51:headline:ea38b6186aeb9341",
      "before_evidence": "https://web.archive.org/web/20190119121737/https://dermavant.com/",
      "before_evidence_kind": "internet_archive",
      "kind": "headline",
      "label": "Headline",
      "summary": "Changed its homepage headline from “Dermavant Sciences Announces Appointment of Dr. Philip M. Brown as Chief Medical Officer” to “Robust Pipeline”.",
      "between": {
        "from": "2019-01-19T12:17:37.000Z",
        "to": "2020-04-09T15:17:34.000Z"
      },
      "evidence": "https://web.archive.org/web/20200409151734/https://www.dermavant.com/",
      "evidence_kind": "internet_archive",
      "basis": "page_facts",
      "topic": null
    },
    {
      "n": 3,
      "id": "page-ffef952de19cba2647f936fb4350b654383ef374d9d8b7315b7885cf7ca13e51:714abb2170698fa373cf0489a6169e684e027b4ae16b4de9f54fdf4d0ae71d90:headline:dfd719366180a1f1",
      "before_evidence": "https://web.archive.org/web/20200409151734/https://www.dermavant.com/",
      "before_evidence_kind": "internet_archive",
      "kind": "headline",
      "label": "Headline",
      "summary": "Changed its homepage headline from “Robust Pipeline” to “Patient‑Focused Innovation”.",
      "between": {
        "from": "2020-04-09T15:17:34.000Z",
        "to": "2021-01-19T11:36:58.000Z"
      },
      "evidence": "https://web.archive.org/web/20210119113658/https://www.dermavant.com/",
      "evidence_kind": "internet_archive",
      "basis": "page_facts",
      "topic": null
    },
    {
      "n": 4,
      "id": "page-714abb2170698fa373cf0489a6169e684e027b4ae16b4de9f54fdf4d0ae71d90:18e169d342339cfb9927629ffdf8b6197227e06fe20be903315c6642fe4b00d1:headline:5865c91092dd19f9",
      "before_evidence": "https://web.archive.org/web/20210119113658/https://www.dermavant.com/",
      "before_evidence_kind": "internet_archive",
      "kind": "headline",
      "label": "Headline",
      "summary": "Changed its homepage headline from “Patient‑Focused Innovation” to “Dermavant Announces Publication of PSOARING 1 & 2 Pivotal Studies of Tapinarof in Plaque Psoriasis in The New England Journal of Medicine”.",
      "between": {
        "from": "2021-01-19T11:36:58.000Z",
        "to": "2022-01-03T15:50:39.000Z"
      },
      "evidence": "https://web.archive.org/web/20220103155039/https://www.dermavant.com/",
      "evidence_kind": "internet_archive",
      "basis": "page_facts",
      "topic": null
    },
    {
      "n": 5,
      "id": "page-18e169d342339cfb9927629ffdf8b6197227e06fe20be903315c6642fe4b00d1:1a0ce86498644abd75706515e00cd04a793651f5c5140a22ff53207100227234:headline:172df89aec5e8808",
      "before_evidence": "https://web.archive.org/web/20220103155039/https://www.dermavant.com/",
      "before_evidence_kind": "internet_archive",
      "kind": "headline",
      "label": "Headline",
      "summary": "Changed its homepage headline from “Dermavant Announces Publication of PSOARING 1 & 2 Pivotal Studies of Tapinarof in Plaque Psoriasis in The New England Journal of Medicine” to “Dermavant Reports Positive Topline Results from ADORING 1, the Second Atopic Dermatitis Phase 3 Trial of VTAMA ® (tapinarof) Cream, 1% in…”.",
      "between": {
        "from": "2022-01-03T15:50:39.000Z",
        "to": "2023-09-26T18:06:58.000Z"
      },
      "evidence": "https://web.archive.org/web/20230926180658/https://www.dermavant.com/",
      "evidence_kind": "internet_archive",
      "basis": "page_facts",
      "topic": null
    },
    {
      "n": 6,
      "id": "page-1a0ce86498644abd75706515e00cd04a793651f5c5140a22ff53207100227234:3a36da0390b245d7bf384558b9b621fea20f03efb0127347e93445b666419f99:headline:8c4dbb466b1ac607",
      "before_evidence": "https://web.archive.org/web/20230926180658/https://www.dermavant.com/",
      "before_evidence_kind": "internet_archive",
      "kind": "headline",
      "label": "Headline",
      "summary": "Changed its homepage headline from “Dermavant Reports Positive Topline Results from ADORING 1, the Second Atopic Dermatitis Phase 3 Trial of VTAMA ® (tapinarof) Cream, 1% in…” to “Dermavant Announces Approval of Tapinarof in both Psoriasis and Atopic Dermatitis in Japan”.",
      "between": {
        "from": "2023-09-26T18:06:58.000Z",
        "to": "2024-07-01T17:46:01.000Z"
      },
      "evidence": "https://web.archive.org/web/20240701174601/https://dermavant.com/",
      "evidence_kind": "internet_archive",
      "basis": "page_facts",
      "topic": null
    },
    {
      "n": 7,
      "id": "page-1a0ce86498644abd75706515e00cd04a793651f5c5140a22ff53207100227234:3a36da0390b245d7bf384558b9b621fea20f03efb0127347e93445b666419f99:compliance:9337a1fa8f602109",
      "before_evidence": "https://web.archive.org/web/20230926180658/https://www.dermavant.com/",
      "before_evidence_kind": "internet_archive",
      "kind": "compliance",
      "label": "Compliance",
      "summary": "Now states FDA APPROVED compliance on its homepage.",
      "between": {
        "from": "2023-09-26T18:06:58.000Z",
        "to": "2024-07-01T17:46:01.000Z"
      },
      "evidence": "https://web.archive.org/web/20240701174601/https://dermavant.com/",
      "evidence_kind": "internet_archive",
      "basis": "page_facts",
      "topic": "https://startuphistory.org/t/added-compliance"
    },
    {
      "n": 8,
      "id": "page-3a36da0390b245d7bf384558b9b621fea20f03efb0127347e93445b666419f99:65b5a0bce08d1b2559f02d3a51a472715e5a058061edf07b8de9f7931d6ca620:headline:6c5297745437a70e",
      "before_evidence": "https://web.archive.org/web/20240701174601/https://dermavant.com/",
      "before_evidence_kind": "internet_archive",
      "kind": "headline",
      "label": "Headline",
      "summary": "Changed its homepage headline from “Dermavant Announces Approval of Tapinarof in both Psoriasis and Atopic Dermatitis in Japan” to “Organon, here for her health”.",
      "between": {
        "from": "2024-07-01T17:46:01.000Z",
        "to": "2026-11-05T13:25:50.690Z"
      },
      "evidence": "https://www.organon.com/",
      "evidence_kind": "live_capture",
      "basis": "page_facts",
      "topic": null
    }
  ],
  "update": {
    "headline": "Dermavant shifts homepage messaging to “Organon, here for her health”",
    "summary": "Dermavant’s site has moved from product trial and approval news toward a new homepage headline referencing Organon, while also adding FDA APPROVED language. Earlier messaging focused on clinical results and approvals for tapinarof.",
    "points": [
      {
        "text": "Between September 2023 and July 2024, Dermavant changed its homepage headline to “Dermavant Announces Approval of Tapinarof in both Psoriasis and Atopic Dermatitis in Japan”.",
        "kind": "fact",
        "changes": [
          6
        ]
      },
      {
        "text": "Between September 2023 and July 2024, the company homepage began stating FDA APPROVED compliance.",
        "kind": "fact",
        "changes": [
          7
        ]
      },
      {
        "text": "Between July 2024 and November 2026, Dermavant changed its homepage headline to “Organon, here for her health”.",
        "kind": "fact",
        "changes": [
          8
        ]
      },
      {
        "text": "The move from headlines about tapinarof approvals to “Organon, here for her health” may suggest a shift in how Dermavant is positioning itself or its relationship with Organon on its homepage.",
        "kind": "interpretation",
        "changes": [
          6,
          8
        ]
      }
    ],
    "written_at": "2026-11-07T15:42:14.245Z",
    "basis": "ai_analysis",
    "model": "gpt-5.1-2025-11-13"
  },
  "method": {
    "version": "messaging-v1",
    "description": "https://startuphistory.org/method"
  },
  "license": "CC-BY-4.0",
  "cite": "StartupHistory, “Dermavant” company record, https://startuphistory.org/c/dermavant.com"
}